# US 2015/0147321 A1 · Pharmaceutical composition comprising antibody composition which specifically binds to ccr4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147321 A1
- Document ID: US20150147321A1
- Status: Published application
- Kind: A1
- Application number: 14/613,668
- Filed: 2015-02-04
- Published: 2015-05-28
- Earliest claimed: 2009-09-10
- Assignees: Kyowa Hakko Kirin Co., Ltd.
- Applicants: Kyowa Hakko Kirin Co., Ltd
- Inventors: Toshihiko ISHII; Miyoko ASANO
- Web page: https://patentgrep.com/patent/US20150147321A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composition comprising a recombinant antibody against CCR4 and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A method for treating non-Hodgkin's disease, comprising administering a recombinant antibody which specifically binds to human CC chemokine receptor 4 and Lenalidomide, wherein said recombinant antibody comprises complementarity determining region (CDR) 1, CDR2 and CDR3 of an antibody heavy chain variable region which comprise the amino acid sequences of SEQ ID NOs: 5, 6 and 7, respectively, and CDR1, CDR2 and CDR3 of an antibody light chain variable region which comprise the amino acid sequences of SEQ ID NOs: 8, 9 and 10, respectively.

### Claim 10 (depends on 9)

The method according to claim 9, which comprises simultaneously or sequentially administering the recombinant antibody and Lenalidomide.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the tumor is a tumor which expresses CCR4.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the recombinant antibody is an antibody having a high antibody-dependent cellular cytotoxicity.

### Claim 13 (depends on 9)

The method according to claim 9, wherein the recombinant antibody is a humanized antibody.

### Claim 14 (depends on 13)

The method according to claim 13, wherein, in the humanized antibody, the heavy chain variable region of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 11, and the light chain variable region of the antibody molecule comprises the amino acid sequence of SEQ ID NO: 12.

### Claim 15 (depends on 9)

The method according to claim 9, wherein the non-Hodgkin's disease is selected from the group consisting of a precursor T-lymphoblastic leukemia/lymphoma, a mature T-cell tumor, and a natural killer cell tumor.
